Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Equillium (0A4D) Share Price & Analysis

0A4D Stock Chart & Stats

$1.38$0.06(4.15%)
At close: 2:47 PM GMT
$1.5$2$2.510 Aug24 Aug8 Sep21 Sep5 Oct19 Oct2 Nov
Day’s Range
$1.38 - $1.38
52-Week Range
$0.83 - $3.53
Previous Close
$1.33
Volume
N/A
Average Volume (3M)
2,185
Market Cap
$86.87M
Enterprise Value
$301.20M
Total Cash (Recent Filing)
$57.16M
Total Debt (Recent Filing)
$584.00K
Price to Earnings (P/E)
―
Beta
0.13
Next Earnings
Nov 18, 2026 (Est.)
EPS Estimate
-0.05
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

EQ504 Clinical Advancement

Initiating human dosing advances EQ504 from preclinical development into clinical testing and creates a structured path toward proof-of-mechanism data. The trial’s safety, pharmacokinetic and pharmacodynamic assessments may help validate the colon-targeted approach and support later ulcerative-colitis studies.

Extended Cash Runway

Additional financing materially extends the period in which Equillium can fund planned development without an immediate financing requirement. A runway into 2029 supports continued EQ504 testing, planned proof-of-concept work and more deliberate strategic execution.

Low Financial Leverage

Very low debt reduces fixed financial obligations and leaves the company with a relatively conservative capital structure for a clinical-stage biotech. This gives management greater flexibility to direct available capital toward trials and pipeline development rather than debt servicing.

Bears Say

No Current Revenue And Continuing Losses

The absence of current revenue means Equillium does not yet have an operating commercial base to offset research and development spending. Continued sizeable losses leave financial performance dependent on clinical progress and future funding rather than recurring business operations.

Persistent Cash Burn

Sustained negative operating and free cash flow shows that planned operations consume substantial capital over time. Even with the extended runway, ongoing trial spending creates continued dependence on existing cash and access to external financing to maintain development activities.

Ongoing Equity Erosion

Persistent losses can reduce the company’s equity base even while debt remains manageable. If this pattern continues, financial resources may contract between financings, potentially limiting the ability to pursue multiple programs or absorb setbacks in clinical development.

Equillium News

0A4D FAQ

What was Equillium’s price range in the past 12 months?
Equillium lowest share price was $0.83 and its highest was $3.53 in the past 12 months.
What is Equillium’s market cap?
Equillium’s market cap is $86.87M.
When is Equillium’s upcoming earnings report date?
Equillium’s next earnings report is estimated for Nov 18, 2026 (not yet confirmed), which is in 15 days.
How were Equillium’s earnings last quarter?
Equillium released its earnings results on Aug 13, 2026. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.054 by $0.014.
Is Equillium overvalued?
According to Wall Street analysts Equillium’s price is currently Undervalued.
Does Equillium pay dividends?
Equillium does not currently pay dividends.
What is Equillium’s EPS estimate?
Equillium’s EPS estimate is -0.05.
How many shares outstanding does Equillium have?
Equillium has 63,408,080 shares outstanding.
What happened to Equillium’s price movement after its last earnings report?
Equillium reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.054. Following the earnings report the stock price went up 6.573%.
Which hedge fund is a major shareholder of Equillium?
Hedge funds hold Equillium shares: the largest hedge-fund position in Equillium is 1,337,908,491 shares.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology